Stock Incentive Plans

3 Months Ended

Mar. 31, 2023

Share-Based Payment Arrangement [Abstract]

Stock Incentive Plans

Note 8 - Stock Incentive Plans

Stock Options

The following table summarizes stock option activity for the three months ended March 31, 2023:

	Options Outstanding
	Shares		Weighted Average Exercise Price
Outstanding, December 31, 2022		19,000	$	19.60
Options expired / forfeited		-	$	-
Outstanding, March 31, 2023		19,000	$	19.60
Exercisable, March 31, 2023		19,000	$	19.60

No stock options were granted during the three months ended March 31, 2023.

The following table summarizes additional information on the Company’s stock options outstanding at March 31, 2023:

	Options Outstanding						Options Exercisable
Exercise Price	Number Outstanding		Weighted- Average Remaining Contractual Life (Years)		Weighted Average Exercise Price		Number Exercisable		Weighted Average Exercise Price
19.60		19,000		0.09	$	19.60		19,000	$	19.60
Totals		19,000		0.09	$	19.60		19,000	$	19.60

As of March 31, 2023, the Company had no unrecognized compensation expense related to unvested stock options. Total expense related to stock options was zero for the three months ended March 31, 2023.

ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2023 and 2022

(unaudited)

As of March 31, 2023, the intrinsic value of options outstanding or exercisable was zero. There were no options outstanding with an exercise price less than $0.58, the per share closing market price of our common stock at that date.